Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, PBMs were targeted by Congress, NAMS had a CV outcomes preview, and CADL showed prostate cancer benefit.</li><li>LLY partnered GLP-1 access with telehealth Ro and presented oral SERD data in breast cancer, rattling HIMS, LFMD, ARVN, and OLMA. </li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, PBMs were targeted by Congress, NAMS had a CV outcomes preview, and CADL showed prostate cancer benefit.LLY partnered GLP-1 access with telehealth Ro and presented oral SERD data in breast cancer, rattling HIMS, LFMD, ARVN, and OLMA. 

Biopharma Week in Review - December 16, 2024

Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On May 15, 2024, CervoMed Inc. (CRVO) announced financial results for the first quarter of 2024 and provided a business update.</li><li>Enrollment is ongoing in the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB).</li><li>We anticipate enrollment completing in the second quarter of 2024 with topline data from the trial expected in the fourth quarter of 2024.</li></ul>

On May 15, 2024, CervoMed Inc. (CRVO) announced financial results for the first quarter of 2024 and provided a business update.Enrollment is ongoing in the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB).We anticipate enrollment completing in the second quarter of 2024 with topline data from the trial expected in the fourth quarter of 2024.

CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24  Topline Data in 4Q24 

United States

Cervomed Inc. operates as a clinical stage biotechnology company. The Company develops and commercializes drug treatments for dementia with lewy bodies, alzheimer's disease, and other central nervous system disorders. CervoMed serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CervoMed (CRVO US)

Biopharma Week in Review - December 16, 2024

LLY partnered GLP-1 access with telehealth Ro and presented oral SERD data in breast cancer, rattling HIMS, LFMD, ARVN, and OLMA.

Water Tower Research

CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24 Topline Data in 4Q24

On May 15, 2024, CervoMed Inc. (CRVO) announced financial results for the first quarter of 2024 and provided a business update. Enrollment is...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)